| Lastest Insider Transactions Of Apellis Pharmaceuticals, Inc. ( APLS ) |
| Symbol | Company Name | Insider Name | Title | Date | Transation | Share | Price | Amount | File Date |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2024-04-12 | Option Exercise | 1,500 | 13.19 | 19,785 | 2024-04-15 16:09:49 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-04-08 | Sell | 69,107 | 54.17 | 3,743,605 | 2024-04-09 16:25:25 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-04-08 | Option Exercise | 69,107 | 3.76 | 259,842 | 2024-04-09 16:25:25 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2024-04-01 | Sell | 4,000 | 58.66 | 234,640 | 2024-04-02 16:06:31 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2024-04-01 | Option Exercise | 4,000 | 10.03 | 40,120 | 2024-04-02 16:06:31 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2024-03-19 | Sell | 18,681 | 57.18 | 1,068,161 | 2024-03-20 17:18:54 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2024-03-18 | Sell | 9,913 | 56.90 | 564,050 | 2024-03-19 16:03:44 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2024-03-15 | Sell | 184 | 56.46 | 10,389 | 2024-03-18 16:19:22 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2024-03-13 | Sell | 11,220 | 57.56 | 645,838 | 2024-03-14 16:17:21 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-03-08 | Sell | 69,107 | 62.19 | 4,297,549 | 2024-03-11 16:08:32 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-03-08 | Option Exercise | 69,107 | 3.67 | 253,623 | 2024-03-11 16:08:32 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2024-03-06 | Option Exercise | 3,762 | 13.85 | 52,104 | 2024-03-08 07:45:34 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2024-03-01 | Sell | 250,000 | 64.11 | 16,028,706 | 2024-03-05 16:07:01 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2024-03-01 | Option Exercise | 250,000 | 4.20 | 1,050,000 | 2024-03-05 16:07:01 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2024-02-12 | Sell | 781 | 67.77 | 52,926 | 2024-02-13 17:06:56 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2024-02-12 | Sell | 1,148 | 67.77 | 77,796 | 2024-02-13 17:05:03 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2024-02-12 | Sell | 1,431 | 67.77 | 96,974 | 2024-02-13 16:59:31 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2024-02-12 | Sell | 3,962 | 67.77 | 268,492 | 2024-02-13 16:49:52 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-02-12 | Sell | 1,148 | 67.77 | 77,796 | 2024-02-13 16:43:13 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2024-02-12 | Sell | 597 | 67.77 | 40,457 | 2024-02-13 16:38:13 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2024-01-29 | Sell | 906 | 64.14 | 58,109 | 2024-01-31 16:38:44 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2024-01-29 | Sell | 906 | 64.14 | 58,109 | 2024-01-31 16:36:09 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2024-01-29 | Sell | 906 | 64.14 | 58,109 | 2024-01-31 16:34:24 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2024-01-29 | Sell | 835 | 64.14 | 53,555 | 2024-01-31 16:31:31 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2024-01-29 | Sell | 1,250 | 65.12 | 81,402 | 2024-01-31 16:28:12 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2024-01-29 | Sell | 2,843 | 64.14 | 182,345 | 2024-01-31 16:26:28 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2024-01-29 | Sell | 1,250 | 65.22 | 81,524 | 2024-01-31 16:23:50 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-01-29 | Sell | 874 | 64.14 | 56,057 | 2024-01-31 16:21:06 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2024-01-29 | Sell | 367 | 64.14 | 23,539 | 2024-01-31 16:18:50 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2024-01-23 | Sell | 4,286 | 63.69 | 272,975 | 2024-01-24 16:06:20 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2024-01-23 | Sell | 7,378 | 63.69 | 469,905 | 2024-01-24 16:03:55 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2024-01-22 | Sell | 13,431 | 65.00 | 872,961 | 2024-01-23 19:28:59 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2024-01-22 | Sell | 4,184 | 65.00 | 271,943 | 2024-01-23 18:17:03 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2024-01-22 | Sell | 3,413 | 65.00 | 221,831 | 2024-01-23 18:15:34 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2024-01-22 | Sell | 3,551 | 65.00 | 230,801 | 2024-01-23 18:13:17 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2024-01-22 | Sell | 2,593 | 65.00 | 168,535 | 2024-01-23 18:11:00 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2024-01-22 | Sell | 1,738 | 65.00 | 112,963 | 2024-01-23 18:07:12 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2024-01-22 | Sell | 1,607 | 65.00 | 104,449 | 2024-01-23 18:05:11 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-01-22 | Sell | 3,913 | 65.00 | 254,329 | 2024-01-23 18:03:25 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2024-01-22 | Sell | 1,384 | 65.00 | 89,954 | 2024-01-23 18:01:42 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2024-01-22 | Sell | 1,061 | 65.00 | 68,961 | 2024-01-23 18:00:05 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2024-01-17 | Sell | 5,207 | 65.58 | 341,475 | 2024-01-18 16:55:06 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2024-01-17 | Sell | 3,276 | 65.58 | 214,840 | 2024-01-18 16:54:00 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-01-16 | Sell | 1,632 | 66.81 | 109,032 | 2024-01-17 16:47:27 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2024-01-16 | Sell | 864 | 66.81 | 57,723 | 2024-01-17 16:45:04 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2024-01-16 | Sell | 1,632 | 66.81 | 109,032 | 2024-01-17 16:43:45 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2024-01-16 | Sell | 1,631 | 66.81 | 108,965 | 2024-01-17 16:41:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2024-01-16 | Sell | 1,857 | 66.81 | 124,064 | 2024-01-17 16:40:13 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2024-01-16 | Sell | 4,240 | 66.81 | 283,268 | 2024-01-17 16:38:41 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2024-01-16 | Sell | 2,235 | 66.81 | 149,317 | 2024-01-17 16:37:15 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2024-01-16 | Sell | 2,235 | 66.81 | 149,317 | 2024-01-17 16:36:16 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2024-01-16 | Sell | 7,851 | 66.81 | 524,514 | 2024-01-17 16:32:17 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2024-01-16 | Sell | 438 | 66.81 | 29,262 | 2024-01-17 12:24:09 |
| APLS | Apellis Pharmaceuticals, Inc. | Baumal Caroline | Chief Medical Officer | 2024-01-04 | Sell | 2,751 | 60.05 | 165,207 | 2024-01-05 16:14:02 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2023-12-26 | Sell | 303 | 59.70 | 18,089 | 2023-12-28 16:13:12 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2023-12-19 | Sell | 3,905 | 57.23 | 223,472 | 2023-12-20 16:18:12 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2023-12-19 | Option Exercise | 7,905 | 13.85 | 109,484 | 2023-12-20 16:18:12 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2023-12-14 | Option Exercise | 6,274 | 13.19 | 82,754 | 2023-12-15 16:04:49 |
| APLS | Apellis Pharmaceuticals, Inc. | SCHEIBLER LUKAS | Chief Research Officer | 2023-12-01 | Sell | 10,000 | 60.00 | 600,000 | 2023-12-05 19:40:46 |
| APLS | Apellis Pharmaceuticals, Inc. | SCHEIBLER LUKAS | Chief Research Officer | 2023-12-01 | Option Exercise | 10,000 | 13.85 | 138,500 | 2023-12-05 19:40:46 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2023-12-01 | Sell | 110,000 | 60.81 | 6,689,304 | 2023-12-05 19:29:19 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2023-12-01 | Option Exercise | 110,000 | 15.09 | 1,659,900 | 2023-12-05 19:29:19 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2023-12-01 | Sell | 24,000 | 61.13 | 1,467,240 | 2023-12-05 16:21:24 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2023-11-30 | Sell | 14,158 | 54.73 | 774,884 | 2023-12-01 16:11:00 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2023-11-30 | Option Exercise | 14,158 | 10.03 | 142,005 | 2023-12-01 16:11:00 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2023-11-21 | Sell | 5,000 | 48.80 | 244,000 | 2023-11-21 17:36:20 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2023-11-17 | Sell | 8,894 | 49.99 | 444,620 | 2023-11-21 16:36:36 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2023-11-17 | Sell | 24,000 | 49.00 | 1,176,000 | 2023-11-21 16:00:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-11-17 | Sell | 1,250 | 47.74 | 59,675 | 2023-11-20 16:18:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-11-17 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-11-20 16:18:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-11-14 | Option Exercise | 45,000 | 3.76 | 169,200 | 2023-11-15 16:10:16 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-11-08 | Sell | 12,000 | 47.27 | 567,240 | 2023-11-09 16:18:16 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-11-08 | Option Exercise | 17,494 | 2.67 | 46,709 | 2023-11-09 16:18:16 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2023-10-23 | Sell | 132 | 46.04 | 6,077 | 2023-10-24 16:20:19 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2023-10-23 | Sell | 131 | 46.04 | 6,031 | 2023-10-24 16:18:36 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-10-17 | Sell | 1,250 | 48.50 | 60,625 | 2023-10-18 17:43:35 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-10-17 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-10-18 17:43:35 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-10-09 | Sell | 12,000 | 40.38 | 484,560 | 2023-10-10 16:26:37 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-10-09 | Option Exercise | 18,500 | 2.67 | 49,395 | 2023-10-10 16:26:37 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-09-18 | Sell | 1,250 | 45.00 | 56,250 | 2023-09-19 17:05:52 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-09-18 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-09-19 17:05:52 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2023-09-18 | Sell | 20,350 | 44.27 | 900,813 | 2023-09-19 17:03:18 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2023-09-18 | Option Exercise | 9,719 | 29.76 | 289,237 | 2023-09-19 17:03:18 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-09-15 | Sell | 1,250 | 45.34 | 56,675 | 2023-09-18 16:24:24 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-09-15 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-09-18 16:24:24 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-09-08 | Sell | 12,000 | 42.87 | 514,440 | 2023-09-11 16:58:21 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-09-08 | Option Exercise | 18,500 | 2.67 | 49,395 | 2023-09-11 16:58:21 |
| APLS | Apellis Pharmaceuticals, Inc. | SCHEIBLER LUKAS | Chief Research Officer | 2023-09-06 | Sell | 1,756 | 43.01 | 75,526 | 2023-09-07 16:08:01 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2023-08-31 | Sell | 551 | 41.23 | 22,716 | 2023-09-01 16:08:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2023-09-01 | Sell | 150,000 | 41.75 | 6,262,960 | 2023-09-01 16:05:29 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2023-09-01 | Option Exercise | 300,000 | 2.67 | 801,000 | 2023-09-01 16:05:29 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-08-08 | Sell | 12,000 | 23.66 | 283,920 | 2023-08-09 16:08:18 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-08-08 | Option Exercise | 18,500 | 2.67 | 49,395 | 2023-08-09 16:08:18 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-07-21 | Option Exercise | 49,779 | 2.67 | 132,910 | 2023-07-24 17:01:36 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-07-20 | Option Exercise | 50,000 | 2.67 | 133,500 | 2023-07-21 16:13:34 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-07-17 | Sell | 1,250 | 64.79 | 80,988 | 2023-07-18 16:40:51 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-07-17 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-07-18 16:40:51 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2023-07-03 | Sell | 8,510 | 89.98 | 765,730 | 2023-07-06 16:20:15 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2023-07-03 | Sell | 6,779 | 89.97 | 609,928 | 2023-07-06 16:16:48 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2023-07-03 | Option Exercise | 6,779 | 10.03 | 67,993 | 2023-07-06 16:16:48 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-06-20 | Sell | 1,250 | 88.41 | 110,513 | 2023-06-21 16:34:29 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-06-20 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-06-21 16:34:29 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-06-08 | Sell | 12,000 | 91.35 | 1,096,200 | 2023-06-09 16:40:09 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-06-08 | Option Exercise | 18,500 | 2.67 | 49,395 | 2023-06-09 16:40:09 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2023-06-05 | Sell | 69,779 | 88.80 | 6,196,527 | 2023-06-06 16:59:30 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2023-06-05 | Option Exercise | 69,779 | 10.03 | 699,883 | 2023-06-06 16:59:30 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2023-06-01 | Sell | 5,000 | 86.00 | 430,000 | 2023-06-02 16:40:00 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2023-06-01 | Option Exercise | 5,000 | 34.11 | 170,550 | 2023-06-02 16:40:00 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-05-17 | Sell | 1,250 | 88.66 | 110,825 | 2023-05-18 17:12:45 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-05-17 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-05-18 17:12:45 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2023-05-16 | Sell | 30,000 | 85.66 | 2,569,900 | 2023-05-18 17:10:56 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2023-05-16 | Option Exercise | 50,000 | 2.67 | 133,500 | 2023-05-18 17:10:56 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-05-08 | Sell | 12,000 | 92.39 | 1,108,680 | 2023-05-09 17:02:50 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-05-08 | Option Exercise | 18,500 | 2.67 | 49,395 | 2023-05-09 17:02:50 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2023-05-03 | Sell | 5,000 | 82.71 | 413,550 | 2023-05-04 16:40:11 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2023-05-03 | Option Exercise | 5,000 | 15.09 | 75,450 | 2023-05-04 16:40:11 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2023-04-18 | Sell | 30,000 | 82.02 | 2,460,720 | 2023-04-20 16:51:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2023-04-18 | Option Exercise | 50,000 | 2.67 | 133,500 | 2023-04-20 16:51:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-04-17 | Sell | 1,250 | 81.05 | 101,313 | 2023-04-18 16:30:23 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-04-17 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-04-18 16:30:23 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-04-10 | Sell | 12,000 | 78.21 | 938,520 | 2023-04-11 16:20:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-04-10 | Option Exercise | 18,500 | 2.67 | 49,395 | 2023-04-11 16:20:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2023-04-03 | Sell | 500 | 74.05 | 37,025 | 2023-04-05 16:54:53 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2023-04-03 | Sell | 5,000 | 75.00 | 375,000 | 2023-04-05 16:52:41 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2023-04-03 | Option Exercise | 5,000 | 34.11 | 170,550 | 2023-04-05 16:52:41 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2023-04-03 | Sell | 5,000 | 74.05 | 370,250 | 2023-04-05 16:50:25 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2023-04-03 | Option Exercise | 5,000 | 15.09 | 75,450 | 2023-04-05 16:50:25 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2023-03-21 | Sell | 30,000 | 62.74 | 1,882,332 | 2023-03-23 16:55:48 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2023-03-21 | Option Exercise | 157,221 | 3.88 | 609,511 | 2023-03-23 16:55:48 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-03-17 | Sell | 1,250 | 64.03 | 80,038 | 2023-03-21 16:35:27 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-03-17 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-03-21 16:35:27 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-03-08 | Sell | 12,000 | 63.79 | 765,480 | 2023-03-10 17:18:35 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-03-08 | Option Exercise | 18,500 | 2.67 | 49,395 | 2023-03-10 17:18:35 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2023-03-03 | Sell | 5,000 | 63.84 | 319,200 | 2023-03-07 16:53:48 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2023-03-03 | Option Exercise | 5,000 | 15.09 | 75,450 | 2023-03-07 16:53:48 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2023-03-01 | Sell | 500 | 65.33 | 32,665 | 2023-03-02 16:20:16 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2023-02-27 | Option Exercise | 100,000 | 3.76 | 376,000 | 2023-03-01 16:10:23 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2023-02-23 | Sell | 1,646 | 68.76 | 113,179 | 2023-02-27 16:34:36 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2023-02-23 | Sell | 1,104 | 68.76 | 75,911 | 2023-02-27 16:32:17 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-02-17 | Sell | 1,250 | 52.38 | 65,475 | 2023-02-21 16:22:07 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-02-17 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-02-21 16:22:07 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-02-08 | Sell | 12,000 | 54.45 | 653,400 | 2023-02-10 17:00:28 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-02-08 | Option Exercise | 18,500 | 2.67 | 49,395 | 2023-02-10 17:00:28 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2023-02-03 | Sell | 5,000 | 55.85 | 279,250 | 2023-02-06 17:35:53 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2023-02-03 | Option Exercise | 5,000 | 15.09 | 75,450 | 2023-02-06 17:35:53 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2023-02-01 | Sell | 500 | 52.61 | 26,305 | 2023-02-02 16:15:16 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2023-01-30 | Sell | 883 | 52.76 | 46,587 | 2023-01-31 16:51:46 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2023-01-30 | Sell | 883 | 52.76 | 46,587 | 2023-01-31 16:47:56 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2023-01-23 | Sell | 2,955 | 51.58 | 152,419 | 2023-01-25 16:17:44 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2023-01-23 | Sell | 4,479 | 51.58 | 231,027 | 2023-01-25 16:14:36 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-01-17 | Sell | 1,250 | 52.42 | 65,525 | 2023-01-19 16:55:00 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-01-17 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-01-19 16:55:00 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-01-09 | Sell | 12,000 | 46.08 | 552,960 | 2023-01-10 20:07:59 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-01-09 | Option Exercise | 18,500 | 2.67 | 49,395 | 2023-01-10 20:07:59 |
| APLS | Apellis Pharmaceuticals, Inc. | Grossi Federico | Chief Medical Officer | 2023-01-05 | Sell | 2,500 | 48.79 | 121,975 | 2023-01-09 19:02:36 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2023-01-03 | Sell | 5,000 | 50.70 | 253,500 | 2023-01-05 20:00:50 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2023-01-03 | Option Exercise | 5,000 | 15.09 | 75,450 | 2023-01-05 20:00:50 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2023-01-03 | Sell | 500 | 50.70 | 25,350 | 2023-01-05 19:40:15 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2022-12-29 | Option Exercise | 7,000 | 3.67 | 25,690 | 2022-12-30 17:00:16 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2022-04-25 | Sell | 28,200 | 52.06 | 1,467,983 | 2022-12-21 16:13:17 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2022-04-25 | Option Exercise | 49,888 | 4.64 | 231,680 | 2022-12-21 16:13:17 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2022-12-15 | Sell | 1,250 | 52.35 | 65,438 | 2022-12-19 16:37:57 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2022-12-15 | Option Exercise | 1,250 | 2.67 | 3,338 | 2022-12-19 16:37:57 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2022-12-08 | Sell | 12,000 | 47.50 | 570,000 | 2022-12-12 16:28:54 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2022-12-08 | Option Exercise | 18,500 | 2.67 | 49,395 | 2022-12-12 16:28:54 |
